Gut Kidney Axis in Enteric Hyperoxaluria

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT05124886
Status
Recruiting

Conditions

  • Enteric Hyperoxaluria

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Moderately High Oxalate (MOx) Diet — OTHER
    Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.

Study Details

40 subjects with a confirmed diagnosis of IBD or \>6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy controls will be administered a high oxalate diet on Days 0-3 and Days 21-24 with a washout period on Days 4-7 and will be administered 250mg sodium oxalate on Days 8-20, via prepared spinach, from Weil Cornell Medicine's Clinical and Translational Science Center. Subjects will partake in four stool collections, four 24-h urine collections, two blood collections, and four sets of colonic permeability testing.

Key Dates

Start date
Nov 10, 2022
Status verified
May 2026
Primary completion
Mar 1, 2028
Completion
Mar 1, 2028

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Healthy Controls
  • Experimental: Enteric Hyperoxaluria

Primary Outcome Measure

Urinary Oxalate Levels (UOx) [ Time Frame: Day 2-3 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016
Lama Nazzal, MD
Lama Nazzal, MD (PRINCIPAL_INVESTIGATOR)
David Goldfarb, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY